The “dumbbell economy” is facing a sudden and sharp contraction as a new generation of medical interventions transforms the business of weight loss. For decades, the fitness industry relied on the grueling pursuit of calorie deficits and gym memberships, but the rapid adoption of anti-obesity drugs is shifting consumer spending from the treadmill to the pharmacy.
This transition is creating a measurable ripple effect across the health and wellness sector. In South Korea, where a culture of efficiency often drives consumer behavior, the rise of GLP-1 receptor agonists like Wegovy and Mounjaro is coinciding with a decline in commercial gym usage and a surge in studio closures. The shift represents more than just a change in preference; it is a fundamental pivot in how a significant portion of the population manages their body mass.
Data from Shinhan Card’s Massive Data Research Center reveals a stark downturn in the boutique fitness sector. Last year, the number of customers using credit cards at Pilates and yoga studios fell by 12 percent, dropping below the levels recorded during the height of the Covid-19 pandemic in 2021. While these studios saw a modest 3.1 percent increase in 2022, they have suffered a steady decline since, with year-on-year drops of 8.6 percent in 2023, 3.7 percent in 2024, and another 3.1 percent last year.
The pharmacological shift in weight management
The decline in gym attendance is closely mirrored by the explosive growth of prescriptions for anti-obesity drugs. According to data from the office of Rep. Seo Mi-hwa of the Democratic Party, validated prescriptions for medications such as Wegovy and Mounjaro reached 168,677 cases as of November last year—a 152.5 percent increase in just three months.
The appeal lies in the speed and perceived ease of the results. For many, the traditional “exercise and diet” paradigm is being replaced by a medical solution that offers faster short-term weight loss. This is particularly evident in the usage of Mounjaro; claims filed with four major nonlife insurance companies—Samsung Fire and Marine Insurance, DB Insurance, Hyundai Marine and Fire Insurance, and Meritz Fire and Marine Insurance—surged from 24 cases in August of last year to 3,264 in February of this year.
From a clinical perspective, these drugs work by mimicking hormones that target areas of the brain that regulate appetite and food intake. However, the medical community warns that relying solely on medication can be counterproductive. As a physician, I note that rapid weight loss often includes a significant loss of lean muscle mass—a condition known as sarcopenia—which can lower the basal metabolic rate and make long-term weight maintenance more difficult. This creates a medical paradox: the very drugs that make people abandon the gym are the ones that make resistance training more critical than ever to preserve muscle health.
![Boxes of Ozempic and Wegovy made by Novo Nordisk are displayed at a pharmacy in London on March 8, 2024. [REUTERS/YONHAP]](https://koreajoongangdaily.joins.com/data/photo/2026/04/05/9266a513-cfb9-47d1-a8c1-469fdc5ab397.jpg)
A fitness industry in retreat
The commercial gym sector is feeling the pressure of both medical alternatives and changing lifestyle habits. Government data shows that 553 fitness centers filed for closure last year, the second-highest figure on record, trailing only the 567 closures seen in 2024. This exceeds the closure rates seen during the pandemic years of 2020 (431) and 2021 (403).
While anti-obesity drugs are a primary driver, other factors are eroding the traditional gym model. A growing preference for running among people in their 20s and 30s, combined with the proliferation of fitness centers within luxury apartment complexes, has reduced the necessity of paying for a commercial membership.
The financial trade-off is also becoming a deciding factor for consumers. While these medications cost approximately 300,000 won (about $200) per month, some users find this more palatable than the combined cost of a gym membership and expensive personal training sessions.
“I lost about 15 kilograms [33 pounds] after taking Wegovy for around four months,” one user shared. “I don’t feel the demand to go to the gym since I can lose weight without exercising. Even if I regain weight after stopping the medication, I would rather save the money I would spend on a gym and use it for prescriptions.”
Pivoting from weight loss to wellness
To survive the rise of GLP-1 medications, experts suggest the fitness industry must redefine its value proposition. The focus is shifting from “weight loss”—which a pharmacy can now handle—to “health management” and functional longevity.
Lee Eun-hee, a professor of consumer science at Inha University, notes that the industry has been vulnerable due to inconsistent quality. “Consumers who were concerned about the cost of personal training and the quality of unqualified trainers are turning away from the industry,” Lee said. “To compete with obesity drugs, the industry needs to improve the quality of its programs.”
Fitness professionals are already attempting to adapt. A representative from the fitness industry noted that they now frequently consult with members about the necessity of pairing medication with exercise to avoid side effects and muscle wasting, stating, “More members demonstrate interest in Wegovy and Mounjaro than exercise.”
The following table outlines the shifting trends in the fitness and medical weight loss landscape:
| Factor | Traditional Fitness Model | Medical-First Model (GLP-1) |
|---|---|---|
| Primary Goal | Caloric burn & muscle building | Rapid weight reduction |
| Cost Driver | Memberships & Personal Training | Monthly prescriptions (~$200) |
| Consumer Appeal | Long-term lifestyle change | Short-term efficiency |
| Primary Risk | Low adherence/plateaus | Muscle loss & side effects |
Disclaimer: This article is for informational purposes only and does not constitute medical advice. Always consult with a licensed healthcare provider before starting any new medication or exercise regimen.
As the market continues to evolve, the next major checkpoint will be the release of updated clinical data on muscle preservation in patients using long-term GLP-1 therapy, which may force a renewed integration between medical prescriptions and mandatory strength training programs.
Do you think medical weight loss will eventually replace the gym, or will it create a new demand for specialized health coaching? Share your thoughts in the comments below.
